Anthony Rodgers

About Professor Anthony Rodgers

Professorial Fellow, Professoriate

  • Professor of Global Health, Faculty of Medicine, UNSW Sydney
  • Chair of Clinical Epidemiology, Faculty of Medicine, Imperial College of London

Professor Rodgers has a track record in cardiovascular disease prevention, innovation and public-private partnerships, with an interest in scale-able interventions to address major risks to health. He is currently Acting Director of the Cardiovascular Division at The George Institute, Australia and Chair of Clinical Epidemiology, Faculty of Medicine, Imperial College of London.

After graduating in medicine in the United Kingdom he trained in epidemiology and public health in New Zealand. He was the Principal Author of the 2002 World Health Report, the main annual publication for WHO. Professor Rodgers has led developments of an affordable four-in-one cardiovascular combination pill ('polypill'). He led a clinical trial program in economically developed and developing countries, funded by the Wellcome Trust, European Union and others.  

Professor Rodgers also developed a world first cell phone based smoking cessation programme for youth, which disseminated proven health support messages in an age-appropriate, affordable medium.  Over 6,000 patients were involved in clinical trials that demonstrated a 50% increase in quit rates. The service has been rolled out by Departments of Health in NZ, UK and India, with over 2 million users to date. A follow-on program delivering cognitive behavioural therapy for depression prevention was successfully trialled among 1,200 at-risk teenagers.

Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations

JAMA Date published:

Blood pressure lowering for the prevention of REcurrent stroke and Cardiovascular outcomes After acute intracerebral haemorrhage: protocol for an individual Participant data meta-analysis of randomised controlled trials (RECAP-ICH)

Cerebrovascular Diseases Date published:

Suicidal Ideation Effectiveness and Safety Outcomes from the Ketamine for Adult Depression Study (KADS)

Archives of Suicide Research Date published:

Efficacy and Safety of Simultaneous Initiation of SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease or Heart Failure

JACC: Heart Failure Date published:

Related Readings